These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 1683612

  • 21. Beta blockers, Lp(a), hypertension, and reduced basal fibrinolytic activity.
    Glueck CJ, Glueck HI, Hamer T, Speirs J, Tracy T, Stroop D.
    Am J Med Sci; 1994 May; 307(5):317-24. PubMed ID: 7909648
    [Abstract] [Full Text] [Related]

  • 22. Benefits of non-selective versus cardioselective beta-blockers in acute myocardial infarction in hypertensive patients.
    Hansen O, Johansson BW.
    J Hypertens Suppl; 1993 Jun; 11(4):S55-60. PubMed ID: 8104242
    [Abstract] [Full Text] [Related]

  • 23. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus.
    Petersen KR.
    Dan Med Bull; 2002 Feb; 49(1):43-60. PubMed ID: 11894723
    [Abstract] [Full Text] [Related]

  • 24. [Relation of an increase of von Willebrand factor in the blood, acute myocardial infarction, unstable angina and coronary thrombosis].
    Mossard JM, Wiesel ML, Cazenave JP, Grunebaum L, Drawin T, Kieny JR, Roul G, Bareiss P, Sacrez A.
    Arch Mal Coeur Vaiss; 1989 Nov; 82(11):1813-8. PubMed ID: 2514633
    [Abstract] [Full Text] [Related]

  • 25. [Does chronic oral treatment with beta-receptor blockers have an effect on positive inotropic therapy of coronary patients with adrenaline after extracorporeal circulation?].
    Günnicker M, Brinkmann M, Freund U, Piotrowski J, Schieffer M, Velser U.
    Herz; 1995 Dec; 20(6):399-411. PubMed ID: 8582699
    [Abstract] [Full Text] [Related]

  • 26. [Aerobic training guidelines in beta blocker therapy. An update].
    Samitz G.
    Wien Med Wochenschr; 1991 Dec; 141(18-19):399-405. PubMed ID: 1685605
    [Abstract] [Full Text] [Related]

  • 27. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE, Philipp T.
    Dtsch Med Wochenschr; 2006 Nov 10; 131(45):2545-50. PubMed ID: 17091442
    [Abstract] [Full Text] [Related]

  • 28. [Pharmacological basis for the therapy of cardiovascular disease with beta-adrenoceptor blocking drugs (author's transl)].
    Lemmer B.
    Herz; 1982 Jun 10; 7(3):168-78. PubMed ID: 6124492
    [Abstract] [Full Text] [Related]

  • 29. [The effect of doxazosin on blood pressure, lipids, fibrinogen and plasminogen activator inhibitor. A comparative study among smokers and non-smokers with essential hypertension].
    Daae LN, Kierulf P, Brusletto B, Westheim A, Holme I, Syvertsen JO.
    Tidsskr Nor Laegeforen; 1991 Apr 10; 111(9):1102-5. PubMed ID: 1827216
    [Abstract] [Full Text] [Related]

  • 30. [Fibrinolytic system in patients with myocardial infarction and other coronary disease risk factors].
    Moreno JA, Gálvez MM, Cornudella R, Angós JA, Romero MS, Gutiérrez M.
    Sangre (Barc); 1994 Apr 10; 39(2):111-6. PubMed ID: 8059288
    [Abstract] [Full Text] [Related]

  • 31. Influence of beta-sitosterol on the fibrinolytic potential in rabbits.
    Hoffmann A, Klöcking HP.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988 Apr 10; 115(1-2):189-96. PubMed ID: 2459019
    [Abstract] [Full Text] [Related]

  • 32. Enhanced risk of thromboembolic disease in hypertension from platelet hyperfunction and decreased fibrinolytic activity: has antihypertensive therapy any influence?
    Winther K, Gleerup G, Hedner T.
    J Cardiovasc Pharmacol; 1992 Apr 10; 19 Suppl 3():S21-4. PubMed ID: 1376829
    [Abstract] [Full Text] [Related]

  • 33. Beta blockers: the extended family.
    Hager WD, Messineo FC, Katz AM.
    Adv Intern Med; 1984 Apr 10; 30():201-29. PubMed ID: 6152107
    [Abstract] [Full Text] [Related]

  • 34. Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.
    Johansson JO, Landin K, Johannsson G, Tengborn L, Bengtsson BA.
    Thromb Haemost; 1996 Sep 10; 76(3):422-8. PubMed ID: 8883281
    [Abstract] [Full Text] [Related]

  • 35. [How and to what extent has beta-blocker treatment been established for chronic heart failure?].
    Yokota Y.
    J Cardiol; 1996 Aug 10; 28(2):99-112. PubMed ID: 8814528
    [Abstract] [Full Text] [Related]

  • 36. The effect of beta adrenergic blockade upon exercise-induced changes in blood coagulation and fibrinolysis.
    Britton BJ, Wood WG, Smith M, Hawkey C, Irving MH.
    Thromb Haemost; 1976 Apr 30; 35(2):396-402. PubMed ID: 9703
    [Abstract] [Full Text] [Related]

  • 37. Tissue plasminogen activator release and plasminogen activator inhibitor levels in coronary artery disease.
    Meyers DG, Haire WD, Rasmussen JK, Boyd EJ.
    Angiology; 1991 Jul 30; 42(7):561-7. PubMed ID: 1907440
    [Abstract] [Full Text] [Related]

  • 38. Prostacyclin synthesis in relation to sympathoadrenal activation. Effects of beta-blockade.
    Pettersson K, Hansson G, Björkman JA, Ablad B.
    Circulation; 1991 Dec 30; 84(6 Suppl):VI38-43. PubMed ID: 1683609
    [Abstract] [Full Text] [Related]

  • 39. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.
    Aznar J, Estellés A, Tormo G, Sapena P, Tormo V, Blanch S, España F.
    Br Heart J; 1988 May 30; 59(5):535-41. PubMed ID: 3132963
    [Abstract] [Full Text] [Related]

  • 40. Effects of stress and beta-blockade on platelet function.
    Hjemdahl P, Larsson PT, Wallén NH.
    Circulation; 1991 Dec 30; 84(6 Suppl):VI44-61. PubMed ID: 1683610
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.